DE69507112D1 - Verwendung eines Serotoninagonisten in Kombination mit einem Tachykininrezeptorantagonisten zur Herstellung eines Arzneimittels zur Prävention oder Behandlung der Migräne - Google Patents

Verwendung eines Serotoninagonisten in Kombination mit einem Tachykininrezeptorantagonisten zur Herstellung eines Arzneimittels zur Prävention oder Behandlung der Migräne

Info

Publication number
DE69507112D1
DE69507112D1 DE69507112T DE69507112T DE69507112D1 DE 69507112 D1 DE69507112 D1 DE 69507112D1 DE 69507112 T DE69507112 T DE 69507112T DE 69507112 T DE69507112 T DE 69507112T DE 69507112 D1 DE69507112 D1 DE 69507112D1
Authority
DE
Germany
Prior art keywords
migraines
prevention
treatment
combination
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69507112T
Other languages
English (en)
Other versions
DE69507112T2 (de
Inventor
Marlene Lois Cohen
Kirk Willis Johnson
Lee Alan Phebus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69507112D1 publication Critical patent/DE69507112D1/de
Publication of DE69507112T2 publication Critical patent/DE69507112T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69507112T 1994-10-05 1995-10-03 Verwendung eines Serotoninagonisten in Kombination mit einem Tachykininrezeptorantagonisten zur Herstellung eines Arzneimittels zur Prävention oder Behandlung der Migräne Expired - Fee Related DE69507112T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/318,391 US5744482A (en) 1994-10-05 1994-10-05 Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine

Publications (2)

Publication Number Publication Date
DE69507112D1 true DE69507112D1 (de) 1999-02-18
DE69507112T2 DE69507112T2 (de) 1999-06-10

Family

ID=23237987

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69507112T Expired - Fee Related DE69507112T2 (de) 1994-10-05 1995-10-03 Verwendung eines Serotoninagonisten in Kombination mit einem Tachykininrezeptorantagonisten zur Herstellung eines Arzneimittels zur Prävention oder Behandlung der Migräne

Country Status (12)

Country Link
US (1) US5744482A (de)
EP (1) EP0710479B1 (de)
AT (1) ATE175347T1 (de)
AU (1) AU4130196A (de)
DE (1) DE69507112T2 (de)
DK (1) DK0710479T3 (de)
ES (1) ES2125567T3 (de)
GR (1) GR3029666T3 (de)
IL (1) IL115451A0 (de)
SI (1) SI0710479T1 (de)
WO (1) WO1996011000A1 (de)
ZA (1) ZA958173B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
MX9703988A (es) * 1994-12-12 1998-02-28 Omeros Med Sys Inc SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
WO1996041633A1 (en) * 1995-06-08 1996-12-27 Eli Lilly And Company Methods of treating cold and allergic rhinitis
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine
GB9620777D0 (en) * 1996-10-07 1996-11-20 Merck Sharp & Dohme Therapeutic use
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
DE19917347A1 (de) * 1999-04-16 2000-11-09 Gsf Forschungszentrum Umwelt Verfahren und Vorrichtung zum trockenen Anbringen von Substanzen an inhalierbare pulverförmige Trägerstoffe
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
JP2010538976A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 肺炎連鎖球菌感染の治療における治療剤としての、濾胞性ゴナドトロピン放出ペプチドの使用

Also Published As

Publication number Publication date
DE69507112T2 (de) 1999-06-10
US5744482A (en) 1998-04-28
AU4130196A (en) 1996-05-02
SI0710479T1 (en) 1999-06-30
ZA958173B (en) 1997-04-01
ES2125567T3 (es) 1999-03-01
EP0710479B1 (de) 1999-01-07
IL115451A0 (en) 1995-09-28
WO1996011000A1 (en) 1996-04-18
DK0710479T3 (da) 1999-08-30
GR3029666T3 (en) 1999-06-30
EP0710479A1 (de) 1996-05-08
ATE175347T1 (de) 1999-01-15

Similar Documents

Publication Publication Date Title
DE69507112D1 (de) Verwendung eines Serotoninagonisten in Kombination mit einem Tachykininrezeptorantagonisten zur Herstellung eines Arzneimittels zur Prävention oder Behandlung der Migräne
BR9106977A (pt) Metodo para suprimir destruicao autoimune de celuias beta pancreaticas,formulacao farmaceutica,metodo de profilaxia,metodo para prevenir o surgimento de diabetes tipo 1 e metodo para tratar um mamifero
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
DE69734006D1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda-antagonist
NO2013017I2 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
DE69435171D1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
AR008444A1 (es) Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
EA200100284A1 (ru) Агонисты 5ht1 рецепторов и метоклопрамид для лечения мигрени
Hovell Comparison of buprenorphine, pethidine and pentazocine for the relief of pain after operation
Jain et al. Analgesic efficacy of low-dose intrathecal neostigmine in combination with fentanyl and bupivacaine for total knee replacement surgery
Ryu et al. Analgesic effects of palonosetron in the intravenous propofol injection
Chen et al. Naloxone prolongs cutaneous nociceptive block by lidocaine in rats
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
Okutomi et al. Prophylactic epidural naloxone reduces the incidence and severity of neuraxial fentanyl-induced pruritus during labour analgesia in primiparous parturients
Dunn et al. Grooming behavior induced by ACTH involves cerebral cholinergic neurons and muscarinic receptors
Vadhanan et al. Comparison of postoperative analgesia with 0.8 mg and 1.6 mg intrathecal nalbuphine; a randomized controlled trial
ATE247965T1 (de) Paracetamol und buspiron enthaltende pharmazeutische zusammensetzung mit analgetischer wirkung
Yoo et al. Evaluation of palonosetron for the prevention of pain on injection of LCT/MCT propofol: Randomized controlled comparison with lidocaine
Heim et al. The effects of the 21-aminosteroid U-74389G on spatial orientation in rats after a cerebral oligemic episode and iron-induced oxidative stress
Calvey et al. Kinetics of intravenous pyridostigmine in man.
DE69923698D1 (de) Verwendung von 3-(1h-imidazol-4-ylmethyl)-indan-5-ol zur herstellung eines medikamentes zur intraspinalen, intrathekalen und epiduralen anwendung
ÖZTÜRK et al. Perineural meperidine blocks nerve conduction in a dose‐related manner: a randomized double‐blind study
KUBOTA et al. SUPPRESSIVE EFFECT OF CIRAMADOL ON THE BRADYKINININDUCED ACTIVITIES OF THE LAMINA V-TYPE CELLS OF THE RAT SPINAL DORSAL HORN

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee